Fiona is the Chief Scientific Officer and a founder of Heptares Therapeutics a clinical-stage company which is using structure based drug discovery to design innovative medicines directed at G protein-coupled receptors (GPCRs). Heptares have generated a pipeline of medicines for diseases including Alzheimer’s, schizophrenia and ADHD. Fiona and her research team have solved the X-ray structures of over 10 novel GPCRs and several of which, including the first Class B structure have recently been published in the journal Nature. Fiona has 25 years’ experience in drug discovery from GSK and Millenium Pharmaceuticals. She is currently Vice Chair of the Wellcome Trust Seeding Drug Discovery committee and is on the Board of Trustees of Alzheimer’s Research UK.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.